Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jay N Cohn

Showing results (151-160 of 171) with videos related to

Pageof 18
Sort By:
European Journal of Heart Failure|February 24, 2015
Loss in body weight is an independent prognostic factor for mortality in chronic heart failure: insights from the GISSI-HF and Val-HeFT trialsPatrick Rossignol, Serge Masson, Simona Barlera, et al.
Journal of the American College of Cardiology|September 13, 2002
Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic studyMaylene Wong, Lidia Staszewsky, Roberto Latini, et al.
Journal of Cardiac Failure|September 18, 2017
Heart Failure With Recovered Ejection Fraction in African Americans: Results From the African-American Heart Failure TrialKay-Won Chang, Neil Beri, Nghia H Nguyen, et al.
Circulation|August 17, 2005
Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFTInder S Anand, Michael A Kuskowski, Thomas S Rector, et al.
Circulation|March 21, 2007
Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African-American Heart Failure TrialAnne L Taylor, Susan Ziesche, Clyde W Yancy, et al.
Journal of Cardiac Failure|March 31, 2009
Endothelial nitric oxide synthase (NOS3) polymorphisms in African Americans with heart failure: results from the A-HeFT trialDennis M McNamara, S William Tam, Michael L Sabolinski, et al.
Circulation|November 6, 2002
Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT)Roberto Latini, Serge Masson, Inder Anand, et al.
Journal of the American College of Cardiology|October 19, 2004
Task force 2: Investigator participation in clinical researchRobert M Califf, Steven E Nissen, Anthony N DeMaria, et al.
European Journal of Heart Failure|December 4, 2014
Calculated plasma volume status and prognosis in chronic heart failureHua Zen Ling, Julia Flint, Morten Damgaard, et al.
Journal of the American College of Cardiology|November 3, 2018
sST2 Predicts Outcome in Chronic Heart Failure Beyond NT-proBNP and High-Sensitivity Troponin TMichele Emdin, Alberto Aimo, Giuseppe Vergaro, et al.
Pageof 18

Showing results (151-160 of 171) with videos related to

Sort By:
Pageof 18
European Journal of Heart Failure|February 24, 2015
Loss in body weight is an independent prognostic factor for mortality in chronic heart failure: insights from the GISSI-HF and Val-HeFT trialsPatrick Rossignol, Serge Masson, Simona Barlera, et al.
Journal of the American College of Cardiology|September 13, 2002
Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic studyMaylene Wong, Lidia Staszewsky, Roberto Latini, et al.
Journal of Cardiac Failure|September 18, 2017
Heart Failure With Recovered Ejection Fraction in African Americans: Results From the African-American Heart Failure TrialKay-Won Chang, Neil Beri, Nghia H Nguyen, et al.
Circulation|August 17, 2005
Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFTInder S Anand, Michael A Kuskowski, Thomas S Rector, et al.
Circulation|March 21, 2007
Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African-American Heart Failure TrialAnne L Taylor, Susan Ziesche, Clyde W Yancy, et al.
Journal of Cardiac Failure|March 31, 2009
Endothelial nitric oxide synthase (NOS3) polymorphisms in African Americans with heart failure: results from the A-HeFT trialDennis M McNamara, S William Tam, Michael L Sabolinski, et al.
Circulation|November 6, 2002
Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT)Roberto Latini, Serge Masson, Inder Anand, et al.
Journal of the American College of Cardiology|October 19, 2004
Task force 2: Investigator participation in clinical researchRobert M Califf, Steven E Nissen, Anthony N DeMaria, et al.
European Journal of Heart Failure|December 4, 2014
Calculated plasma volume status and prognosis in chronic heart failureHua Zen Ling, Julia Flint, Morten Damgaard, et al.
Journal of the American College of Cardiology|November 3, 2018
sST2 Predicts Outcome in Chronic Heart Failure Beyond NT-proBNP and High-Sensitivity Troponin TMichele Emdin, Alberto Aimo, Giuseppe Vergaro, et al.
Pageof 18